The United States Food and Drug Administration (USFDA) has granted Zydus Lifesciences final approval to manufacture and market Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg (USRLD: Zyprexa Zydis Orally Disintegrating Tablets). 5 mg, 10 mg, 15 mg, and 20 mg Olanzapine Orally Disintegrating Tablets USP are used to treat certain mental/mood conditions (such as schizophrenia and bipolar disorder).
Olanzapine tablets can also be used in conjunction with other antidepressant medications to treat depression. These tablets are classified as atypical antipsychotics and work by restoring the balance of certain natural substances in the brain. The products will be manufactured in Moraiya, Ahmedabad, at the group’s formulation manufacturing facility (India). In the United States, sales of Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg totaled USD 28.3 million (IQVIA MAT Dec. 2022).